AstraZeneca stock: analysis & valuation

AZNDrug Manufacturers - GeneralUnited KingdomData as of Nov 15, 2026
Metrics analysis · Drug Manufacturers - General

AstraZeneca AZN

Price 184.45 USD +0.04%Market cap 286.1 bn USD52 weeks 153.41 – 212.71
Forward P/E
16.3x
Industry 15.9x
EV/EBITDA
14.7x
Industry 13.6x
Revenue growth
6.7%
Industry 5.8%
Operating margin
25.8%
Industry 31.5%
Return on equity
22.6%
Industry 20.2%
Free cash flow yield
2.0%
Industry 3.8%

What does AstraZeneca do?

AstraZeneca is a British-Swedish pharmaceutical group that researches, develops, manufactures, and markets prescription medicines worldwide. Its focus is on oncology, cardiovascular, renal, and metabolic diseases, respiratory and immune diseases, and rare diseases. Its portfolio includes Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Farxiga, and Symbicort, among others.

Revenue arises from the sale of patent-protected drugs to wholesalers, hospitals, pharmacies, and government healthcare systems, as well as from licensing and collaboration income. Key sales markets are the US, Europe, and China. In competition with other large companies in the sector, AstraZeneca is among the leading providers in cancer medicine. The company relies on a broad research pipeline, collaborations with partners such as Daiichi Sankyo, and targeted acquisitions to replace expiring patents with new active ingredients.

Score profile

Quality6.1
Valuation5.3
Growth7.8
Financial strength3.2
Momentum6.5

Rank vs. Drug Manufacturers - General (18 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.

Metrics compared with the industry

On profitability and quality, AstraZeneca ranks above average in the group Drug Manufacturers - General (6.1/10). On growth, the company ranks above average in the group Drug Manufacturers - General (7.8/10). On valuation (higher = cheaper), the stock ranks in the middle in the group Drug Manufacturers - General (5.3/10). On financial strength, AstraZeneca ranks below average in the group Drug Manufacturers - General (3.2/10).

MetricStockGroup medianRanking
Forward P/E16.3x15.9xbetter than 42 %
Trailing P/E26.1x26.9xbetter than 59 %
PEG ratio1.3x3.3xbetter than 88 %
EV/EBITDA14.7x13.6xbetter than 36 %
Price/sales4.6x4.2xbetter than 47 %
Price/book5.5x5.5xbetter than 56 %
Revenue growth6.7%5.8%better than 58 %
Earnings growth23.5%-2.8%better than 97 %
Gross margin81.8%74.2%better than 86 %
Operating margin25.8%31.5%better than 31 %
Net margin17.7%14.3%better than 69 %
Return on equity22.6%20.2%better than 58 %
Debt/equity66.3%105.3%better than 64 %
Current ratio1.0x1.4xbetter than 25 %
Free cash flow yield2.0%3.8%better than 8 %
Dividend yield1.7%2.3%–
Payout ratio45.4%63.3%–
Beta0.150.31–

Valuation: what is AstraZeneca worth?

Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give AstraZeneca a model range of 75.53 USD to 179.92 USD per share.

Price 184.45 USD
Analysts 208.07 USD
Fair value range 75.53 USD – 179.92 USDMidpoint 121.37 USD (−34.2% vs. price)

12 analysts, average rating “Buy”, average price target 208.07 USD (+12.8%).

The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.

What the business depends on

  • Success depends heavily on patent-protected core products, especially in oncology.
  • Approvals and market access for new active ingredients and additional indications broaden the revenue base.
  • A productive research pipeline and successful collaborations secure replacements for expiring patents.

Risks

  • Patent expirations and generic or biosimilar competition can significantly reduce revenue from established drugs.
  • Clinical trials or approval procedures can fail and write off costly development projects.
  • Price regulation, reimbursement pressure, and trade policy interventions in the main markets weigh on margins.

What to look for with AstraZeneca

The operating margin is particularly informative because it shows how profitable drug sales remain after high research and distribution costs.

Full AI analysis of AstraZeneca

The AI evaluates all the numbers above and turns them into an assessment with a score, strengths and weaknesses, a fair value range and risks – from €1.99; Plus (€4.99) adds business model, moat and scenarios, Pro (€9.99) also peer comparison and reverse DCF. See an example.

Analyze a stock

Results in minutes
1 Choose a stock
2 Choose the depth

See what you get first: Example Compact (Apple) PDF Plus example (Microsoft) PDF Example Pro (NVIDIA) PDF

3 Delivery
Secure payment via Stripe Report by email + PDF No subscription

Frequently asked questions about AstraZeneca stock

What is the P/E ratio of AstraZeneca stock?

Based on expected earnings, AstraZeneca trades at a P/E of 16.3x, compared with a median of 15.9x for the peer group Drug Manufacturers - General. Based on the earnings of the last twelve months it is 26.1x. (data as of Nov 15, 2026)

Does AstraZeneca pay a dividend?

Yes. The dividend yield is currently 1.7%, with a payout ratio of 45.4% of earnings.

Is AstraZeneca stock undervalued?

Measured by valuation metrics (P/E, EV/EBITDA, price/sales, PEG), AstraZeneca is currently valued roughly in line with the average of the companies in the group Drug Manufacturers - General (valuation score 5.3 out of 10). Our model calculations (DCF and industry multiples) give a range of 75.53 USD to 179.92 USD per share at a price of 184.45 USD. This is a model calculation, not an investment recommendation.

What do analysts say about AstraZeneca stock?

12 analysts have an average price target of 208.07 USD (+12.8% vs. the current price); the average rating is “Buy”. Analyst targets are opinions and change frequently.

Comparable stocks

All information without guarantee. Metrics from public market data, updated daily; company profile written editorially with the help of AI. Not investment advice and not a solicitation to buy or sell securities.